Revolution Medicines, Inc.
Revolution Medicines, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on precision oncology. It develops small-molecule therapies designed to target RAS-addicted cancers, with its pipeline centered on RAS(ON) inhibitors and related combination approaches.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaSmall-molecule therapies designed to inhibit the active, GTP-bound form of RAS in cancer cells.
Clinical and preclinical oncology programs built around genetic drivers and resistance biology.
Programs that test RAS-targeted agents with other therapies to improve response and durability.
Research collaboration arrangements that support discovery and biomarker work.
Asiakkaat
The company’s direct counterparties are primarily pharmaceutical collaborators, research partners, and contract manufacturers rather than end-market patients. If approved, its future customers would be oncologists, hospitals, cancer centers, and third-party payors that determine access and reimbursement for targeted cancer medicines.
Pharmaceutical and biotech partners that support discovery, preclinical work, or biomarker programs.
Cancer centers and physicians that enroll patients and generate clinical data for pipeline advancement.
Oncologists who would prescribe approved RAS-targeted therapies in relevant cancer indications.
Commercial insurers and government programs that determine coverage, pricing, and reimbursement.
Strategia
The company is building a portfolio of RAS(ON) inhibitors for RAS-addicted cancers and intends to retain meaningful development and commercialization rights. Its strategy combines internal drug discovery with collaborations, biomarker work, and combination-therapy development to improve the odds of clinical differentiation.
Clinical proof of concept is central to validating the platform and creating future product value.
Combination regimens and biomarker insights can improve response rates and patient selection.
A direct launch model requires medical, regulatory, manufacturing, and market access readiness.
Maantiede
Revolution Medicines is headquartered in the United States and expects its first commercial launch, if approved, to be in the U.S. before expanding to Europe and Asia. Its development and commercialization model is global in scope, but manufacturing is outsourced to third-party CDMOs and future market access will depend on country-specific reimbursement systems.
Riskit
The business depends on successful clinical development of unproven RAS-targeted therapies, and failure in preclinical or clinical studies would materially impair the platform. As a clinical-stage biotech with no approved products, it also faces substantial financing, regulatory, manufacturing, and reimbursement risk before any commercial revenue can scale.
- Clinical development failureVaikutus: KriittinenTodennäköisyys: Kohtalainen
Pipeline value depends on demonstrating safety and efficacy in human trials.
Kohdistuu: Lead RAS(ON) inhibitor programs
- Financing riskVaikutus: KorkeaTodennäköisyys: Korkea
The company will need substantial capital before product sales can fund operations.
Kohdistuu: Development and commercialization build-out
- Scientific uncertainty around direct RAS inhibitionVaikutus: KorkeaTodennäköisyys: Kohtalainen
The target has historically been difficult to drug, so the mechanism may not translate into durable approvals.
Kohdistuu: RAS(ON) platform
- Manufacturing and supply dependenceVaikutus: KeskitasoTodennäköisyys: Kohtalainen
All manufacturing is outsourced to CDMOs, creating third-party execution and quality risk.
Kohdistuu: Clinical and future commercial supply
- Reimbursement and pricing pressureVaikutus: KeskitasoTodennäköisyys: Matala
Oncology drugs depend on coverage decisions and may face price controls or negotiation.
Kohdistuu
Kirjanpito
Harkinnanvaraiset erätClinical and preclinical vendor invoices may lag service delivery, so estimates affect reported expenses and liabilities.
Vaikutus: Can shift quarterly operating loss materially
Revenue from research agreements depends on performance obligations and contract termination terms.
Vaikutus: Affects timing and amount of non-product revenue
The Royalty Purchase Agreement requires fair-value estimates of future royalty payments.
Vaikutus: Can create significant non-cash balance-sheet and P&L volatility
Upfront payments to vendors are recognized over the period services are received.
Vaikutus: Affects expense timing across reporting periods
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Black Diamond Therapeutics, Inc.
BDTX · Biological Products, (No Diagnostic Substances)
Erasca, Inc.
ERAS · Pharmaceutical Preparations
BridgeBio Oncology Therapeutics, Inc.
BBOT · Pharmaceutical Preparations
Praxis Precision Medicines, Inc.
PRAX · Pharmaceutical Preparations
Replimune Group, Inc.
REPL · Biological Products, (No Diagnostic Substances)
RenovoRx, Inc.
RNXT · Surgical & Medical Instruments & Apparatus
Päivitetty: 24.9.2026